TNG

Transgene is a clinical-stage French biotechnology company specializing in the design and development of virus-based immunotherapies for cancer treatment. The company leverages its proprietary platforms, myvac and Invir.IO, to create individualized neoantigen therapeutic vaccines and multifunctional oncolytic viruses. Its lead program, TG4050, is an individualized vaccine currently in Phase I/II trials for head and neck cancer, developed in collaboration with NEC Corporation. Transgene also advances TG4001, a therapeutic vaccine targeting HPV-16 positive cancers, and a portfolio of oncolytic viruses including BT-001 and TG6050. With a focus on stimulating the patient's immune system to specifically destroy tumor cells, Transgene maintains strategic partnerships with major industry players like AstraZeneca.